OPTR » Topics » Item 9.01 Financial Statements and Exhibits.

This excerpt taken from the OPTR 8-K filed Nov 3, 2009.

Item 9.01                     Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated November 3, 2009.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

OPTIMER PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ John D. Prunty

 

 

John D. Prunty
Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

Date:  November 3, 2009

 

3


This excerpt taken from the OPTR 8-K filed Aug 5, 2009.

Item 9.01                     Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated August 5, 2009.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

OPTIMER PHARMACEUTICALS, INC.

 

 

 

 

By: 

/s/ John D. Prunty

 

 

John D. Prunty

 

 

Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

 

 

Date:  August 5, 2009

 

 

 

3


This excerpt taken from the OPTR 8-K filed May 7, 2009.

Item 9.01     Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated May 7, 2009.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
OPTIMER PHARMACEUTICALS, INC.
 
 

 

By:

/s/ John D. Prunty

 

 

John D. Prunty
Chief Financial Officer (Duly Authorized Officer and
Principal Financial and Accounting Officer)

 

Date:  May 7, 2009

 

3


This excerpt taken from the OPTR 8-K filed Mar 11, 2009.

Item 9.01   Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated March 11, 2009.

 

 

 

 

2



SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
 
OPTIMER PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ John D. Prunty

 

 

John D. Prunty

 

 

Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

Date:  March 11, 2009

 

3


 

This excerpt taken from the OPTR 8-K filed Mar 5, 2009.

Item 9.01     Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description

 

 

 

4.1

 

 

Form of Warrant.

 

 

 

 

  5.1

 

 

Opinion of Cooley Godward Kronish LLP.

 

 

 

 

23.1

 

 

Consent of Cooley Godward Kronish LLP (included in its opinion filed as Exhibit 5.1 hereto).

 

 

 

 

99.1

 

 

Form of Common Stock Purchase Agreement.

 

 

 

 

99.2

 

 

Form of Unit Purchase Agreement.

 

 

 

 

99.3

 

 

Press release of Optimer Pharmaceuticals, Inc. dated March 5, 2009.

 

1



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

OPTIMER PHARMACEUTICALS, INC.

 

 

 Dated: March 5, 2009

By:

/s/ John D. Prunty

 

 

John D. Prunty

 

 

Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

2


This excerpt taken from the OPTR 8-K filed Jan 13, 2009.

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Summary of Optimer Pharmaceuticals, Inc. 2009 Incentive Compensation Plan

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

OPTIMER PHARMACEUTICALS, INC.

 

 

Dated: January 13, 2009

By:

/s/ John D. Prunty

 

 

John D. Prunty
Chief Financial Officer (Duly Authorized Officer
and Principal Financial and Accounting Officer)

 

3


This excerpt taken from the OPTR 8-K filed Nov 5, 2008.

Item 9.01     Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated November 5, 2008.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
 
OPTIMER PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ John D. Prunty

 

 

John D. Prunty
Chief Financial Officer (Duly Authorized Officer and
Principal Financial and Accounting Officer)

 

Date:  November 5, 2008

 

3


This excerpt taken from the OPTR 8-K filed Oct 8, 2008.

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Optimer Pharmaceuticals, Inc. Severance Benefit Plan.

 

 

 

99.2

 

Amendment to Employment Agreement between Optimer Pharmaceuticals, Inc. and Michael N. Chang.

 

 

 

99.3

 

Amendment to Offer Letter between Optimer Pharmaceuticals, Inc. and Kevin Poulos.

 

 

 

99.4

 

Amendment to Offer Letter between Optimer Pharmaceuticals, Inc. and John D. Prunty.

 

2



 

SIGNATURES

 

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

OPTIMER PHARMACEUTICALS, INC.

 

 

 

 Dated: October 8, 2008

By:

/s/ John D. Prunty

 

 

 

 

 

John D. Prunty

 

 

Chief Financial Officer (Duly Authorized Officer
and Principal Financial and Accounting Officer)

 

3


This excerpt taken from the OPTR 8-K filed Aug 6, 2008.

Item 9.01                     Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated August 6, 2008.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
 
 
OPTIMER PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ John D. Prunty

 

 

 

John D. Prunty

 

 

 

Chief Financial Officer (Duly Authorized Officer and

 

 

 

Principal Financial and Accounting Officer)

 

Date:  August 6, 2008

 

3


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki